Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis

Nephrology Dialysis Transplantation

Volumn 27, Issue 9, 2012, Pages 3552-3559

  Yang, Xiao Wei ^a,b,c,d   Tan, Ying ^a,b,c,d   Yu, Feng ^a,b,c,d   Zhao, Ming Hui ^a,b,c,d  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

^b PEKING UNIVERSITY   (China)

^c BEIJING HOSPITAL   (China)

^d BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

anti C1q autoantibody; anti dsDNA autoantibody; autoantibodies; lupus nephritis

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; BETA2 GLYCOPROTEIN 1 ANTIBODY; C REACTIVE PROTEIN; COMPLEMENT COMPONENT C1Q ANTIBODY; CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA; DOUBLE STRANDED DNA ANTIBODY; LEFLUNOMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHINESE; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE ACTIVITY; FEMALE; HEMATURIA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INCIDENCE; KIDNEY BIOPSY; KIDNEY DISEASE; LEUKOCYTURIA; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REMISSION;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, ANTINUCLEAR; AUTOANTIBODIES; COMPLEMENT C1Q; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; FOLLOW-UP STUDIES; HUMANS; KIDNEY DISEASES; LUPUS NEPHRITIS; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; YOUNG ADULT;

EID: 84865708432     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs179     Document Type: Article

References (28)

1. Cervera R, Khamashta MA, Font J et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82: 299-308.
2. Swaak T, Smeenk R. Clinical significance of antibodies to double stranded DNA (dsDNA) for systemic lupus erythematosus (SLE). Clin Rheumatol 1987; 6(Suppl 1): 56-73.
3. Okamura M, Kanayama Y, Amastu K et al. Significance of enzyme linked immunosorbent assay (ELISA) for antibodies to double stranded and single stranded DNA in patients with lupus nephritis: correlation with severity of renal histology. Ann Rheum Dis 1993; 52: 14-20.
4. Linnik MD, Hu JZ, Heilbrunn KR et al. Relationship between antidouble-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. Arthritis Rheum 2005; 52: 1129-1137.
5. Sinico RA, Radice A, Ikehata M et al. Anti-C1q autoantibodies in lupus nephritis: prevalence and clinical significance. Ann N Y Acad Sci 2005; 1050: 193-200.
6. Marto N, Bertolaccini ML, Calabuig E et al. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus. Ann Rheum Dis 2005; 64: 444-448.
7. Fang QY, Yu F, Tan Y et al. Anti-C1q antibodies and IgG subclass distribution in sera from Chinese patients with lupus nephritis. Nephrol Dial Transplant 2009; 24: 172-178.
8. Trendelenburg M, Lopez-Trascasa M, Potlukova E et al. High prevalence of anti-C1q antibodies in biopsy-proven active lupus nephritis. Nephrol Dial Transplant 2006; 21: 3115-3121.
9. Do NA, Viana VS, Testagrossa LA et al. Antibodies to ribosomal P proteins: a potential serologic marker for lupus membranous glomerulonephritis. Arthritis Rheum 2006; 54: 1568-1572.
10. Alba P, Bento L, Cuadrado MJ et al. Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritis. Ann Rheum Dis 2003; 62: 556-560.
11. Tan Y, Yu F, Yang H et al. Autoantibodies against monomeric C-reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial lesions. Hum Immunol 2008; 69: 840-844.
12. Sjowall C, Zickert A, Skogh T et al. Serum levels of autoantibodies against C-reactive protein correlate with renal disease activity and response to therapy in lupus nephritis. Arthritis Res Ther 2009; 11: R188.
13. Katsumata Y, Miyake K, Kawaguchi Y et al. Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis: a controlled study of 126 consecutive patients. Arthritis Rheum 2011; 63: 2436-2444.
14. Trendelenburg M. Anti-C1q antibodies as a diagnostic marker of proliferative lupus nephritis: comment on the article by Katsumata et al. Arthritis Rheum 2012; 64: 324-325, 325-326.
15. Matrat A, Veysseyre-Balter C, Trolliet P et al. Simultaneous detection of anti-C1q and anti-double stranded DNA autoantibodies in lupus nephritis: predictive value for renal flares. Lupus 2011; 20: 28-34.
16. Moroni G, Radice A, Giammarresi G et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis 2009; 68: 234-237.
17. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.
18. Bombardier C, Gladman DD, Urowitz MB et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992; 35: 630-640.
19. Bombardieri S, Vitali C, Caponi L et al. Activity criteria in systemic lupus erythematosus. Clin Exp Rheumatol 1994; 12(Suppl 11): S45-S48.
20. Vitali C, Bencivelli W, Isenberg DA et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin Exp Rheumatol 1992; 10: 541-547.
21. Yu F, Tan Y, Liu G et al. Clinicopathological characteristics and outcomes of patients with crescentic lupus nephritis. Kidney Int 2009; 76: 307-317.
22. Weening JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004; 65: 521-530.
23. Austin HR, Boumpas DT, Vaughan EM et al. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 1994; 45: 544-550.
24. Austin HR, Muenz LR, Joyce KM et al. Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 1984; 25: 689-695.
25. Petri M, Genovese M, Engle E et al. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 1991; 34: 937-944.
26. Esdaile JM, Abrahamowicz M, Joseph L et al. Laboratory tests as predictors of disease exacerbations in systemic lupus erythematosus. Why some tests fail. Arthritis Rheum 1996; 39: 370-378.
27. Pickering MC, Botto M, Taylor PR et al. Systemic lupus erythematosus, complement deficiency, and apoptosis. Adv Immunol 2000; 76: 227-324.
28. Tan Y, Zhou W, Yu F et al. Detection of anti-C1q antibodies and anti-C1q globular head domain antibodies in sera from Chinese patients with lupus nephritis. Mol Immunol 2009; 46: 2178-2182.